Belgium's pharmaceutical sector is facing mounting domestic pressure from analysts concerned about the undermining of ...

Thank you, Operator, and welcome, everyone, to the Nanalysis Scientific’s fourth quarter and full year 2024 conference call.

(Nasdaq: GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by ...

Pittsburgh biotech firms see potential benefits from upcoming tariffs and reshoring efforts, despite uncertainties in NIH ...

Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025Cocrystal Pharma's pan-viral ...

Merck, Bristol Myers Squibb, Sanofi and Roche had little clarity on the potential impact of President Donald Trump’s ...

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” first quarter ...

Companies are announcing significant investments in U.S. manufacturing in response to looming tariffs. An AstraZeneca ...

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of ...

Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political threats. The big story: ...

Pharmaceutical firm Shield Therapeutics has admitted that US tariffs spell risks and uncertainties for its business.

I was at the fourth Shared Island Forum in Dublin Castle earlier this month when the Taoiseach, Micheál Martin, gave one of ...